To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

Global News

The Institute of Medical Science, the University of Tokyo, and Astellas Enter into an Agreement for Expansion of the Scope of Collaborative Research Utilizing Rice-Based Oral Vaccine"MucoRice" Technology

May 11, 2017

Tokyo, May 11, 2017 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that they have signed an agreement for expansion of the scope of collaborative research utilizing the rice-based oral vaccine “MucoRice” (“MucoRice”) to viral gastroenteritis diarrhea*1 including norovirus*2 infection.

MucoRice is a rice-based oral vaccine genetically expressing antigens and suppressing the endogenous rice storage protein, which was developed by Prof. Hiroshi Kiyono, Project researcher Yoshikazu Yuki and their colleagues at International Research and Development Center for Mucosal Vaccines in IMSUT.

Since 2016, IMSUT and Astellas have been engaged in the project for collaborative research on vaccines against cholera*3 and enterotoxigenic Escherichia coli*4 utilizing MucoRice system. MucoRice is the rice-based oral vaccine which activates the mucosal immune system in the intestine and induces a protective immunity. Thus, the scope of collaborative research will be expanded to viral gastroenteritis diarrhea*1 including norovirus*2 infection where unmet medical needs remain.

Through this collaborative research project, IMSUT and Astellas will promote research on vaccines against infectious diseases seriously affecting social life and new treatments, and attempt to develop the new drug discovery technology platform for development of innovative new drugs and hope we can address unmet medical needs.

###

 

Printer-friendly version


Main Text end
Local Navigation
Local Navigation end
Related Links